ERBB2 and breast carcinoma: We used breast cancer (BC) as a prototype disease and the cell lines JIMT-1 and MDA-MB-468 as prototypes for two difficult-to-treat breast cancer subtypes, BC refractory to HER2 therapy (JIMT-1) and triple negative BC (MDA-MB-468).